Charles Rose
Infectious Disease · Lexington, KYNPI 1568595874
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,682 of the $67,767 with a category attached, or 68.9%. 25 manufacturers reported payments, led by Shionogi Inc at 32.5% of the total. 2025 is the largest year on record at $27,217, more than ten times the $1,020 reported in 2019. Among infectious disease clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 729 payments — averaging $92.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shionogi Inc$22K
- La Jolla Pharmaceutical Company$18K
- Viiv Healthcare Company$17K
- Gilead$3K
- Astrazeneca UK Limited$1K
- Insmed, Inc.$1K
- plus $5K from 19 others
Across 4 payments — averaging $25,805 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$103K
What the payments were for
- Speaking & faculty fees$46,68269%
- Travel & lodging$4,4707%
- Food & beverage$15,57523%
- Education$1,0402%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shionogi Inc | 91 | $22,057 |
| La Jolla Pharmaceutical Company | 53 | $17,936 |
| Viiv Healthcare Company | 121 | $16,928 |
| Gilead | 122 | $2,993 |
| Astrazeneca UK Limited | 9 | $1,428 |
| Insmed, Inc. | 65 | $1,327 |
| Astellas Pharma US Inc | 49 | $1,217 |
| Merck | 65 | $1,093 |
| Paratek Pharmaceuticals, Inc. | 46 | $779 |
| Melinta Therapeutics, LLC | 39 | $703 |
| Aimmune Therapeutics, Inc. | 15 | $299 |
| Tetraphase Pharmaceuticals, Inc. | 11 | $262 |
| AbbVie(2 entities) | 10 | $163 |
| Pfizer | 7 | $106 |
| Theratechnologies Inc. | 4 | $81 |
| Ferring Pharmaceuticals Inc. | 5 | $81 |
| Mayne Pharma Commercial LLC | 4 | $72 |
| Cumberland Pharmaceuticals, Inc. | 3 | $66 |
| Johnson & Johnson | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $29 |
| Invivyd Inc | 1 | $27 |
| Romark Laboratories, LC | 2 | $21 |
| Vyera Pharmaceuticals, LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Angiodynamics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,767 in reported general payments places this provider in the 90th percentile of 100 infectious disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ArikayceAmikacin Liposomal/Neb.Accessr | 13 | $204,289 |
| DovatoDolutegravir Sodium/Lamivudine | 55 | $165,029 |
| RukobiaFostemsavir Tromethamine | 11 | $87,652 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 16 | $62,849 |
| JulucaDolutegravir/Rilpivirine | 11 | $44,381 |
| Daptomycin | 36 | $37,939 |
| CeftriaxoneCeftriaxone Sodium | 71 | $13,302 |
| ErtapenemErtapenem Sodium | 13 | $8,633 |
| Doxycycline Monohydrate | 273 | $8,247 |
| Methenamine Hippurate | 116 | $7,916 |
| Epinephrine | 32 | $7,343 |
| Vancomycin Hcl | 46 | $5,462 |
| Cephalexin | 201 | $4,503 |
| Linezolid | 13 | $3,831 |
| Cefepime Hcl | 17 | $3,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Rukobia, Juluca | $16,928 | $297,06277 claims |
| Insmed, Inc.Arikayce | $1,327 | $204,28913 claims |
| GileadBiktarvy | $2,993 | $62,84916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 100 infectious disease providers in Kentucky.
Other infectious disease in Lexington
- David DoughertyLexington$145K
- Marty AllenLexington$40K
- Daniel RodrigueLexington$37K
- John MeekLexington$12K
- Mark DoughertyLexington$12K
- Andrea BanksLexington$11K
- Takako SchaningerLexington$8K
- Andrew AlexanderLexington$7K
- Richard GreenbergLexington$6K
- Elizabeth PiercyLexington$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.